Search

Mile Brujic, OD, FAAO Partner Premier Vision Group Bowling Green, OH This activity was written by PER[R] editorial staff under faculty guidance and review. Faculty, Staff, and Planners' Disclosures In [...]

The small number of new drug approvals in 2016 -- only 22 (1)--may have been an anomaly. As of Nov. 14, 2017, FDA's Center for Drug Evaluation and Research (CDER) [...]

Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015, leading analysts to believe that all the [...]

The oncology sector is slated to heat up in the first half of 2018, with the CAR-T frenzy showing no signs of slowing down. Last year ended with headline-grabbing news [...]

Event In October the merchandise trade surplus (excluding precious metals) amounted to CHF3.5bn (US$3.5bn), on par with the balance recorded in October 2018, according to unadjusted data from the Swiss [...]

INNOVATION 15 STILL VALUED IN THE ORPHAN-DRUG SPACE, BUT THE REIMBURSEMENT BAR IS RISING. NPS PHARMA'S EPIC PAUWELS, WHO'S LAUNCHED FIVE ULTRA-RARE DISEASE PRODUCTS, EXPLAINS HOW THESE BIOTECH BRANDS CAN [...]

Pharma and biotech companies are hoping for a recovery in R&D productivity to replace aging blockbusters. But any rebound in new product approvals will have to wait until the research [...]

Although the leading pharmaceutical companies are often termed multinationals, their regional origins are still important. Several studies have suggested that the idea of a global company that transcends national boundaries [...]

Second to market and dismissed as inferior to the competition, Sanofi's Aubagio seemed destined for lower-tier status. Here's how it overcame the initial obstacles and, five years later, become a [...]

Continuous processing is attracting attention in the manufacture of both small-molecule drugs and biopharmaceuticals. In small-molecule manufacturing, flow chemistry has many advantages, including increased development speeds, improved product and process [...]

A new round of pharmaceutical industry mergers and acquisitions (M&As) are on the horizon, judging by the series of announcements and rumours circulating the media during the first half of [...]

STEIN, Switzerland -- Novartis AG predicts that its drug sales growth will be below the market average this year and revenues probably won't increase more than [...]

STARTING IN 2010, the traditional multiple sclerosis market was upended by the introduction of three oral drugs. First came the approval of Gilenya, from Novartis, followed by Sanofi's Aubagio, in [...]

On July 7, FDA approved sacubitril/valsartan (Entresto, Novartis) orally administered tablets for the treatment of Class II to Class IV chronic heart failure with reduced ejection fraction. The drug has [...]

Joanne K. Wuensch Harris Nesbitt 212-883-5115 joanne.wuensch@harrisnesbitt.com COVERAGE: Medical Technology OUTLOOK: It was an outstanding quarter, in our opinion, for surgical and pharmaceutical products, which continued their double-digit gains (resulting [...]

NEW YORK -- The rankings of pharmaceutical sales leaders in the United States are changing, based in part on how innovator companies are adjusting to generic competition. According to IMS [...]